HC Wainwright & Co. Initiates Coverage On Monte Rosa Therapeutics with Buy Rating, Announces Price Target of $25

Benzinga · 2d ago
HC Wainwright & Co. analyst Mitchell S. Kapoor initiates coverage on Monte Rosa Therapeutics (NASDAQ:GLUE) with a Buy rating and announces Price Target of $25.